Fulminant progression of demyelinating disease after valproate-induced encephalopathy.
We report the clinical, radiologic, and pathologic features of a patient who had fulminant demyelinating disease and who experienced acute progression of his disease after an episode of valproate-induced hyperammonemic encephalopathy. The role hyperammonemia played in the progression of the demyelination is uncertain. This case raises concern of a possible risk with the use of valproic acid in the subset of patients with fulminant demyelinating disease.
Blindauer
K A
KA
Department of Neurology, Medical College of Wisconsin, Milwaukee, USA.
Harrington
G
G
Morris
G L
GL
Ho
K C
KC
D000328:Adult; D000927:Anticonvulsants; D001933:Brain Stem / Q000473:pathology; D002540:Cerebral Cortex / Q000473:pathology; D000075202:Contraindications; D003711:Demyelinating Diseases / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D004660:Encephalitis / Q000139:chemically induced* / Q000175:diagnosis / Q000473:pathology; D006801:Humans; D008297:Male; D014635:Valproic Acid
D000927:Anticonvulsants; D014635:Valproic Acid